{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:14:50Z","timestamp":1780499690776,"version":"3.54.1"},"reference-count":59,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of multiple autoantibodies, resulting in tissue and organ damage. Recent studies have revealed that interleukin-23 (IL-23) and interleukin-27 (IL-27) may be therapeutically relevant in selected SLE manifestations. This study aimed to identify associations between serum IL-27 and IL-23 levels and disease activity in Polish patients with different manifestations of SLE: neuropsychiatric lupus (NPSLE), and lupus nephritis (LN). Associations between interleukin levels and oligo-specific antibodies against double-stranded DNA (dsDNA), dose of glucocorticoids, and type of treatment were also analyzed. An enzyme-linked immunosorbent assay was used to assess anti-dsDNA antibodies and analyze the serum concentration of IL-27 and IL-23 from 72 patients aged 19\u201374 years with confirmed active SLE. Disease activity was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2-K). No significant correlations between interleukin levels and SLEDAI score, anti-dsDNA, corticosteroid dose, or type of treatment were noted. Patients with NPSLE and LN presented the highest median scores of SLEDAI.<\/jats:p>","DOI":"10.3390\/jcm10204788","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T03:01:13Z","timestamp":1634698873000},"page":"4788","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-5980","authenticated-orcid":false,"given":"Katarzyna","family":"Pawlak-Bu\u015b","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Rehabilitation and Internal Medicine, Pozna\u0144 University of Medical Sciences, 61-701 Pozna\u0144, Poland"},{"name":"Department of Rheumatology and Osteoporosis, J. Stru\u015b Municipal Hospital in Pozna\u0144, 61-285 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9409-9827","authenticated-orcid":false,"given":"Wiktor","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rehabilitation and Internal Medicine, Pozna\u0144 University of Medical Sciences, 61-701 Pozna\u0144, Poland"},{"name":"Department of Rheumatology and Osteoporosis, J. Stru\u015b Municipal Hospital in Pozna\u0144, 61-285 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Leszczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rehabilitation and Internal Medicine, Pozna\u0144 University of Medical Sciences, 61-701 Pozna\u0144, Poland"},{"name":"Department of Rheumatology and Osteoporosis, J. Stru\u015b Municipal Hospital in Pozna\u0144, 61-285 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nrrheum.2013.103","article-title":"Diagnostic criteria for systemic lupus erythematosus: Has the time come?","volume":"9","author":"Bertsias","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3111\/13696998.2013.772058","article-title":"Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population","volume":"16","author":"Furst","year":"2013","journal-title":"J. Med. Econ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: Core Curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102780","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: A review","volume":"20","author":"Monfort","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrneurol.2014.148","article-title":"Neuropsychiatric systemic lupus erythematosus: Pathogenesis and biomarkers","volume":"10","author":"Muller","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5114\/reum.2015.51507","article-title":"Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008\u20132012","volume":"53","author":"Brzozowska","year":"2015","journal-title":"Reumatologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/156652409787847263","article-title":"Cytokines in systemic lupus erythematosus","volume":"9","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"365083","DOI":"10.1155\/2010\/365083","article-title":"Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances","volume":"2010","author":"Yap","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_11","first-page":"839","article-title":"Recent advances in cytokines in cutaneous and systemic lupus erythematosus","volume":"38","author":"Mikita","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12379","DOI":"10.1111\/jcmm.15737","article-title":"IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis","volume":"24","author":"Xu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/08916934.2019.1693545","article-title":"Th1, Th2, and Th17 cytokines in systemic lupus erythematosus","volume":"53","author":"Wong","year":"2020","journal-title":"Autoimmunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1186\/ar3194","article-title":"Increased interleukin-23 receptor+ T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"12","author":"Puwipirom","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4049\/jimmunol.0900939","article-title":"IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons","volume":"183","author":"Curtis","year":"2009","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4049\/jimmunol.180.2.922","article-title":"IL-27 induces a Th1 immune response and susceptibility to experimental arthritis","volume":"180","author":"Cao","year":"2008","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"L133","DOI":"10.1152\/ajplung.00307.2015","article-title":"IL-27 enhances innate immunity of human pulmonary fibroblasts and epithelial cells through upregulation of TLR4 expression","volume":"310","author":"Su","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2310\/JIM.0b013e3181d88f7b","article-title":"Low level of serum interleukin 27 in patients with systemic lupus erythematosus","volume":"58","author":"Li","year":"2010","journal-title":"J. Investig. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/JLB.3AB0518-180RR","article-title":"The cytokine network Type I Interferon, IL-27 and IL-10 is augmented in murine and human lupus","volume":"106","author":"Lee","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.arcmed.2010.02.011","article-title":"IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus","volume":"41","author":"Leng","year":"2010","journal-title":"Arch. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejr.2012.04.002","article-title":"Interleukin-27 and its relation to disease parameters in SLE patients","volume":"34","author":"Gaber","year":"2012","journal-title":"Egypt. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/1110-6530.150269","article-title":"Role of interleukin-23 in the immunopathogenesis of systemic lupus erythematosus","volume":"34","author":"Hegab","year":"2014","journal-title":"Egypt. J. Dermatol. Venerol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0300060513509130","article-title":"Associations between serum interleukin-23 levels and clinical characteristics in patients with systemic lupus erythematosus","volume":"42","author":"Du","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/03009742.2014.962080","article-title":"Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: Possible role in lupus nephritis","volume":"44","author":"Xia","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9401432","DOI":"10.1155\/2017\/9401432","article-title":"Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease","volume":"2017","author":"Fischer","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1177\/0961203320952841","article-title":"Interleukin 23 is elevated in the serum of patients with SLE","volume":"29","author":"Vukelic","year":"2020","journal-title":"Lupus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 EULAR\/ACR classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/acr.23292","article-title":"Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data","volume":"70","author":"Leuchten","year":"2018","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/annrheumdis-2019-215845","article-title":"A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: International collaborative study to evaluate a candidate preparation","volume":"78","author":"Fox","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","author":"Liang","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cei.12296","article-title":"Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: Critical remarks","volume":"179","author":"Rekvig","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-015-0702-6","article-title":"Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and responsiveness to patient concerns in clinical research","volume":"17","author":"Mikdashi","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of Physician Global Assessment in systemic lupus erythematosus: A systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1191\/096120399680411335","article-title":"The SLICC\/ACR damage index: Progress report and experience in the field","volume":"8","author":"Gladman","year":"1999","journal-title":"Lupus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","article-title":"The role of IL-23\/IL-17 axis in lupus nephritis","volume":"183","author":"Zhang","year":"2009","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/1381612825666190313140811","article-title":"Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?","volume":"25","author":"Argollo","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI25308","article-title":"Anti\u2013IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis","volume":"116","author":"Chen","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"861028","DOI":"10.1155\/2013\/861028","article-title":"Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice","volume":"2013","author":"Kyttaris","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_44","unstructured":"(2021, October 12). Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus. Available online: https:\/\/www.janssen.com\/janssen-announces-discontinuation-phase-3-lotus-study-evaluating-ustekinumab-systemic-lupus."},{"key":"ref_45","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5021\/ad.2016.28.2.222","article-title":"The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries","volume":"28","author":"Youn","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.15745","article-title":"Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn\u2019s disease patients with prior failure to anti-TNF treatment","volume":"52","author":"Biemans","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13555-021-00490-3","article-title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","volume":"11","author":"Papp","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the Treatment of Refractory Crohn\u2019s Disease: The Spanish Experience in a Large Multicentre Open-label Cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14712598.2019.1561850","article-title":"Anti-interleukin-12 and anti-interleukin-23 agents in Crohn\u2019s disease","volume":"19","author":"Macaluso","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1654067","article-title":"Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn\u2019s disease","volume":"32","author":"Berman","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_54","first-page":"2874","article-title":"Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn\u2019s disease: Report and systematic literature review of effectiveness and safety","volume":"8","author":"Holm","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/14712598.2020.1727437","article-title":"Positioning ustekinumab in moderate-to-severe ulcerative colitis: New kid on the block","volume":"20","author":"Fiorino","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","article-title":"Anti-interleukin-23 agents for the treatment of ulcerative colitis","volume":"20","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/ejd.2021.3965","article-title":"Guselkumab: An anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis","volume":"31","author":"Chiricozzi","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"482","DOI":"10.20452\/pamw.1891","article-title":"New treatment strategy including biological agents in patients with systemic lupus erythematosus","volume":"123","year":"2013","journal-title":"Pol. Arch. Med. Wewn"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.4049\/jimmunol.0900568","article-title":"IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T Cells","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4788\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:18:03Z","timestamp":1760167083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":59,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204788"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204788","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}